1naresh
Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)
1naresh
Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)


Table 4: 
Association of CBF map of pattern 1 with EGFRvIII expression in GBMa
Hyperperfusion (+)bHyperperfusion (−)cTotal
EGFRvIII (+)11112PPV: 91.67%
EGFRvIII (−)131629NPV: 55.17%
Total241741
Sensitivity45.83%
Specificity94.12%
  • Note:—PPV indicates positive predictive value; NPV, negative predictive value; +, present; −, absent.
  • ↵a Of 53 patients, 41 had EGFRvIII expression examined on postsurgical GBM tissue. Fisher exact test P value = .006.
  • ↵b CBF map with pattern 1.
  • ↵c CBF map with pattern 2.